RegenXBio Receives a Buy from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital maintained a Buy rating on RegenXBio (NASDAQ: RGNX), with a price target of $130. The company’s shares closed on Friday at $77.35, close to its 52-week high of $85.10.

According to TipRanks.com, Amusa is a top 100 analyst with an average return of 30.3% and a 56.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for RegenXBio with a $70.75 average price target.

See today’s analyst top recommended stocks >>

Based on RegenXBio’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $104 million. In comparison, last year the company had a GAAP net loss of $14.47 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.